35Pharma Presents HS235 Pre-Clinical Heart Failure and Pulmonary Hypertension Data in Moderated Poster Session at AHA 2025
- Pre-clinical data highlight HS235’s differentiated safety and efficacy profile, that supports ongoing Phase 1b/2a trials in Pulmonary Hypertension due to HFpEF and Pulmonary Arterial Hypertension
35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today presented pre-clinical HS235 data in an oral moderated poster presentation at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, LA.
HS235 is a next-generation BMP-9/-10 sparing Activin Signaling Inhibitor being investigated in patients with heart failure and pulmonary hypertension. HS235 was engineered to achieve high potency against Activin and Growth Differentiation Factor ligands while sparing BMP-9/-10 ligands whose neutralization has been associated with bleeding, telangiectasia and pericardial effusions.
HS235 results presented at the conference included:
- In a pulmonary hypertension due to heart failure (Group 2 PH) model: HS235 reduced cardiac hypertrophy, rescued left ventricular function, and improved pulmonary vascular remodeling and RV function.
- In an obesogenic HFpEF model: HS235 normalized left ventricular pressures and exercise capacity, and increased skeletal muscle mass, reduced fat mass, and improved fat metabolism.
Maureen O’Connor, Ph.D., Chief Scientific Officer of 35Pharma, commented: “By engineering a highly potent Activin Signaling Inhibitor that is sparing of BMP-9/-10, we’ve designed a molecule with the potential for improved safety and efficacy in a broad range of indications. These pre-clinical data highlight HS235’s potential to address both cardiopulmonary remodeling as well as metabolic dysfunction that define PH and Heart Failure, particularly in the context of obesity.”
Two clinical trials have been initiated to evaluate HS235:
- NCT07123779, a Phase 1b study of HS235 in patients with obesity and Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF,Group 2 PH); and
- NCT07143448, a Phase 1b study of HS235 for treatment of Pulmonary Arterial Hypertension (PAH, Group 1 PH).
35Pharma is a clinical-stage biopharmaceutical company focused on the design and development of best-in-class Activin Signaling Inhibitors for Pulmonary Hypertension, obesity and cardiometabolic diseases. 35Pharma’s lead candidate, HS235, is being developed for the treatment of cardiopulmonary diseases with an initial focus on Pulmonary Hypertension and HFpEF.
Julia Schoelermann,
VP Corporate Development, 35Pharma
info@35pharma.com
Other news
Subscribe
To receive our press releases, please subscribe to our mailing list
35Pharma is a biopharmaceutical company focused on designing and developing innovative biologics for diseases with high unmet medical need.